Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

The evolving role of adiponectin as an additive biomarker in HFrEF

Tahnee Sente1,2, Andreas Gevaert3,4, An Van Berendoncks4

  • 1Laboratory for Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Edegem, Belgium. tahnee.sente@uantwerpen.be.

Heart Failure Reviews
|August 3, 2016
PubMed

Insights

Adiponectin has beneficial cardiovascular effects but also plays a role in heart failure (HF). This review examines adiponectin

Area of Science:

  • Cardiology
  • Biochemistry
  • Pathophysiology

Background:

  • Heart failure (HF) is a significant and increasing global health concern.
  • Despite advancements in management, HF prevalence is projected to rise.
  • Adiponectin, a protein hormone, exhibits complex roles in cardiovascular health and disease.

Purpose of the Study:

  • To review current knowledge on adiponectin's role in heart failure with reduced ejection fraction (HFrEF).
  • To explore adiponectin's cardioprotective and anti-inflammatory actions in HFrEF.
  • To assess adiponectin's potential as a biomarker for HF diagnosis and prognosis.

Main Methods:

  • Literature review of existing research on adiponectin and heart failure.
  • Analysis of studies investigating adiponectin's cardiovascular and inflammatory effects.
  • Synthesis of data regarding adiponectin's involvement in HFrEF pathogenesis.

Main Results:

  • Adiponectin demonstrates both protective and detrimental effects in the context of HF.
  • Evidence suggests adiponectin influences cardiac function and inflammation in HFrEF.
  • The protein's dual role necessitates careful consideration in therapeutic strategies.

Conclusions:

  • Adiponectin's complex role in heart failure requires further investigation.
  • Understanding adiponectin's mechanisms may offer new diagnostic and prognostic insights for HFrEF.
  • Targeting adiponectin pathways could represent a future therapeutic avenue for cardiovascular conditions.

Keywords:
AdiponectinBiomarkerCardioprotectionHeart failureInflammation

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
688
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
470